The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma

Key Points

• CAR-T treatment outcomes are influenced by baseline frailty and inflammatory biomarkers, suggesting a significant relationship.
• Inflammatory biomarkers can serve as critical indicators of treatment effectiveness in relapsed refractory myeloma.
• Longitudinal assessment highlights the importance of continuous monitoring of patient's frailty status during treatment.
• Understanding these relationships may enable personalization of CAR-T therapies for better patient management.